StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Other research analysts also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

VNRX opened at $0.63 on Tuesday. The firm has a 50 day simple moving average of $0.65 and a 200 day simple moving average of $0.66. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The company has a market cap of $58.38 million, a price-to-earnings ratio of -1.75 and a beta of 1.20.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares in the company, valued at $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC boosted its stake in VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.